Lv2
130 积分 2025-03-28 加入
Follow-up analysis enhances understanding of molecular residual disease in localized non-small cell lung cancer
2天前
已完结
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
2天前
已完结
Quantitative protein expression of antibody-drug conjugate targets in EGFR mutated and wild-type non-small cell lung cancer
2天前
已完结
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): Safety, efficacy, and exploratory biomarker analysis
2天前
待确认
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer
2天前
已完结
Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a single-center real-world study
5天前
已关闭
Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a single-center real-world study
9天前
已关闭
As neoadjuvant treatment in endobronchial ultrasound confirmed stage IIIA-N2 Non-small cell lung cancer （NSCLC）patients with EGFRmutation（Exon19 or 21）（NCT01217619，Estern）：A prospective single arm，Phase II clinical trial
10天前
已关闭
Comparisons of perioperative outcomes after neoadjuvant therapies in patients with resectable non-small cell lung cancer
10天前
已关闭
A phase II trial of neoadjuvant erlotinib (TARCEVA®) followed by surgery for selected patients with stage IIIA, N2-positive non-small cell lung cancer
10天前
已完结
皖公网安备34019202002308
